Introduction
============

Nicotine is believed to be the primary rewarding and addictive compound in tobacco. It also improves cognition and attention ([@B55]), and may reduce the lifetime risk of developing Parkinson's disease (PD) ([@B65]). These effects are mediated by binding to nicotinic acetylcholine receptors (nAChRs) in the brain ([@B60]; [@B75]; [@B27]). Neuronal nAChRs are pentameric, ligand-gated, cation-selective channels formed from α2 -- α10 and β2 -- β4 subunits. The heteromeric subtypes contain α and β subunits in a 2:3 or 3:2 (α:β) stoichiometric ratio ([@B54]). Neuronal nAChRs are present on presynaptic terminals where they modulate the release of neurotransmitters such as dopamine ([@B23]; [@B14]). The subunit composition of the nAChR subtypes determines their pharmacological and biophysical properties, and partially governs their anatomical and subcellular distribution ([@B34]).

β2-containing (β2^∗^) nAChRs are among the most nicotine-sensitive subtypes in the brain, responding to agonist concentrations in the 0.2--0.5 μM range ([@B50]; [@B36]), and play a crucial role in nicotine reward and reinforcement ([@B61]; [@B49]; [@B83]). Mice with β2 genetic deletions (β2KO) self-administer cocaine ([@B61]), but not nicotine ([@B61]; [@B49]; [@B62]), and β2KO mice fail to show conditioned place preference (CPP) for nicotine ([@B83]). α4β2^∗^ nAChRs are the most common brain subtype, and play a major role in nicotine reward and reinforcement ([@B61]; [@B78]; [@B62]; [@B52]); however, their widespread distribution ([@B23]; [@B4]) means that they may not be the optimal target for smoking cessation, particularly because their persistent activation may induce depressive behavior ([@B33]).

The CNS expression of α6β2^∗^ receptors is more limited than that of α4β2^∗^ nAChRs. α6β2^∗^ nAChRs are selectively expressed in dopaminergic neurons of the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) as well as neurons in the retina, superior colliculus ([@B11]; [@B41]; [@B28]), medial habenula ([@B28]; [@B73]), and locus coeruleus. α6^∗^ nAChRs are also expressed in the peripheral nervous system where they can interact with P2X receptors ([@B38]; [@B84]). The localization of α6β2^∗^ nAChRs on dopaminergic neurons suggests they may play a significant role in nicotine reward and contribute to nicotine-mediated neuroprotection against PD ([@B65]). Indeed, selective activation of hypersensitive α6^∗^ nAChRs in transgenic mice by low doses of nicotine is sufficient to establish CPP ([@B17]). Moreover, α6KO mice fail to self-administer nicotine, a behavior that can be rescued by selectively re-expressing α6^∗^ nAChRs in the VTA ([@B62]). Taken together, these results suggest that α6β2^∗^ nAChRs are potential targets for smoking cessation and PD neuroprotection therapeutics.

α-Conotoxin MII (and derivatives) are useful probes for processes mediated by α6^∗^ nAChRs ([@B3]; [@B58]; [@B30], [@B29]; [@B51]; [@B42]). Pioneering studies also identified a series of drug-like small molecule α6^∗^ nAChR inhibitors ([@B89]). There are also potential, small-molecule α6^∗^-selective agonists that bind to α4β2^∗^ nAChRs and α6β2^∗^ nAChRs ([@B6]; [@B45]) or α6β4 nAChRs ([@B40]).

Here, we introduce a novel nAChR agonist, (E)-5-(pyrimidin-5-yl)-1,2,3,4,7,8-hexahydroazocine (TC299423). We compare TC299423 to other well-characterized nAChR ligands (nicotine and varenicline) using *in vitro* and *in vivo* assays. The results show that TC299423 is a potent agonist for β2^∗^ nAChRs, and may show a modest preference for α6β2^∗^ over α4β2^∗^ nAChRs. Bioavailability assays show that TC299423 enters the brain. Locomotor assays using transgenic mice expressing hypersensitive α6^∗^ nAChRs confirm that TC299423 potently activates α6^∗^ nAChRs *in vivo*. CPP assays using mice with various nicotinic subunit null mutations further suggest that TC299423 acts primarily through α6(non-α4)β2^∗^ nAChRs. Given that β2^∗^ nAChRs are implicated in the anxiolytic effects of nicotine ([@B80]; [@B29]), we use a marble-burying assay to compare the effects of TC299423 to nicotine and varenicline. We also compare the effects of TC299423 to those of nicotine and varenicline for their antinociceptive properties. The results show that TC299423 is a potent nAChR ligand that may useful in the future study of nAChR function and physiology using *in vivo* and *in vitro* models.

Materials and Methods {#s1}
=====================

Mice
----

C57BL/6 mice (ages 3--6 months) used in this study were bred and maintained at the California Institute of Technology (Caltech) or the University of Colorado Boulder. After weaning at 21 days, same sex littermates were housed no more than 4 (Caltech) or 5 (Colorado) to a cage. Mice of the α4 subunit null mutant line ([@B48]), the α6 subunit null mutant line ([@B12]), and the hypersensitive α6L9'S transgenic mice ([@B18]) were bred and maintained as above and genotyped as previously described ([@B48]; [@B11]; [@B19]). Mice had free access to food and water and were maintained on a 12/12-h light/dark cycle at 22°C. All experiments were conducted with the approval of the California Institute of Technology Animal Care and Use Committee. C57BL/6J strain mice, as well as α4, α5, and β2 subunit null mutant mice on this background, were bred and maintained at the Institute for Behavioral Genetics, University of Colorado Boulder, CO, United States. Animal care and procedures were approved by the Animal Care and Utilization Committee of the University of Colorado, Boulder.

Rats
----

Rat experiments were conducted in adherence with the National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee of Mt. Sinai, New York, NY, United States. Male Wistar rats (*n* = 8; Charles River Laboratories, Raleigh, NC) weighing 300 g at the start of experiments were housed in groups of 1--2 per cage in an environmentally controlled vivarium on a 12 h reverse light-dark cycle. Prior to the commencement of behavioral testing, all rats had *ad libitum* access to food and water.

Compounds and Reagents
----------------------

TC299423, (E)-5-(pyrimidin-5-yl)-1,2,3,4,7,8-hexahydroazocine, was synthesized at Targacept. A full report on the synthesis of TC299423 is in preparation. Varenicline tartrate was also synthesized by Targacept. \[^125^I\]-Epibatidine (2200 Ci/mmol), \[^3^H\]dopamine (3,4-\[ring-2,5,6-3H\], 30--60 Ci/mmol), \[^3^H\]choline (methyl-3H, 60--90 Ci/mmol), and carrier-free ^86^RbCl were purchased from Perkin Elmer Life Sciences, Boston, MA, United States. α-Conotoxin MII (α-CtxMII) was obtained from J. Michael McIntosh, University of Utah, Salt Lake City, UT, United States. The following chemicals as well as all buffer components (Reagent Grade) were products of Sigma--Aldrich (St. Louis, MO, United States): (L)-nicotine hydrogen tartrate, mecamylamine, atropine, bovine serum albumin (BSA), (±)-epibatidine, HEPES, nomifensine, pargyline, and tetrodotoxin. All compounds were dissolved in physiological saline (0.9% NaCl). Concentrations refer to the free base.

Biochemistry and Physiology
---------------------------

### Ligand Binding

The methods used for preparing brain membranes in hypotonic buffer have been described previously ([@B44], [@B43]). Brain membrane preparations were stored as pellets under buffer at -70°C or used immediately. We followed previously published methods for \[^125^I\]epibatidine binding and analysis ([@B24]).

### Synaptosome Preparation

Regions of interest were dissected from fresh mouse brains and homogenized in ice-cold isotonic sucrose (0.32 M), buffered with HEPES (5 mM, pH 7.5). The suspension was centrifuged at 12,000 × *g* for 20 min. The pellet was re-suspended in the appropriate uptake buffer ([@B25]; [@B71]; [@B47]) and used immediately.

### \[^3^H\]Dopamine Uptake and Release

Superfusion was carried out at 22°C using a buffer containing: NaCl, 128 mM; KCl, 2.4 mM; CaCl~2~, 3.2 mM; MgSO~4~, 1.2 mM; KH~2~PO~4~, 1.2 mM; HEPES, 25 mM; glucose, 10 mM; ascorbic acid, 1 mM; pargyline, 0.01 mM; 0.1% BSA; nomifensine, 1 μM (to prevent the re-uptake of dopamine); atropine, 1 μM (to prevent muscarinic receptor activation); pH 7.5. Superfusion proceeded at 0.7 mL/min for 10 min before stimulation with agonist for 20 s. Selected aliquots were perfused with α-CtxMII (50 nM) for 3 min immediately before stimulation. This concentration of α-CtxMII was sufficient to inhibit α6β2^∗^-nAChRs in the mouse striatum ([@B71], [@B70]). Fractions (∼0.1 mL) were collected into 96-well plates at 10 s intervals for 4 min (starting ∼1 min before stimulation). After adding 0.15 mL of Optiphase SuperMix scintillation cocktail, radioactivity was measured using a 1450 MicroBeta TriLux counter (Perkin Elmer Life Sciences).

Previously published methods for \[^3^H\]ACh release from crude IPN synaptosomes were followed ([@B25]). Agonist-stimulated ^86^Rb^+^ efflux from synaptosomes was measured using previously described methods ([@B46], [@B43]).

### Neuro-2a Cell Culture

Mouse neuroblastoma 2a (neuro-2a) cells, obtained from ATCC (Cat \#: CCL-131, purchased: January 2012), were cultured using previously described methods ([@B86]). The β2~DM~ subunit bears mutations in the M3--M4 intracellular loop that enhance exit from the endoplasmic reticulum for both α4β2 and α6β2 nAChRs ([@B76]; [@B86]; [@B28]). Cells were transfected with 500 ng of: α4-GFP and β2~DM~ or α6-GFP, β2~DM~, and β3 nAChR subunits. Plasmids were mixed with 250 μL of Opti-MEM reduced serum medium (Life Technologies). Lipofectamine 2000 (Life Technologies) was separately added to 250 μL of Opti-MEM. After 5 min at 24°C, DNA and Lipofectamine solutions were combined and incubated for another 25 min at 24°C. The resulting solution was added to pre-plated neuro-2a cells and incubated for 24 h. After 24 h, the Opti-MEM was removed and replaced with culture medium.

### Patch-Clamp Recordings

For the patch-clamp experiments, we used mouse neuro-2a cells. 50,000 neuro-2a cells (transfected as described above) were plated onto sterilized 12 mm glass coverslips (Deckgläser, Prague, Czechia), placed in 35-mm culture dishes, and cultured in a humidified incubator (37°C, 95% air, 5% CO~2~). Transfected cells displaying eGFP fluorescence were identified for patching using an inverted epifluorescence microscope. The pipette solution contained (in mM): 135 K gluconate, 5 KCl, 5 EGTA, 0.5 CaCl~2,~ 10 HEPES, 2 Mg-ATP, and 0.1 GTP (pH adjusted to 7.2 with Tris-base, osmolarity adjusted to 280--300 mOsm with sucrose). The resistance of the patch pipettes was 2--4 MΩ. The extracellular solution contained (in mM): 140 NaCl, 5 KCl, 2 CaCl~2~, 1 MgCl~2~, 10 HEPES, and 10 glucose (320 mOsm, pH set to 7.3 with Tris-base). The cells were voltage-clamped in whole-cell mode using an Axopatch 1D amplifier (Axon Instruments), and the data were recorded with a Digidata 1440A analog-to-digital converter (Axon Instruments) and the pCLAMP V.10 software (Axon Instruments). The data were sampled at 10 kHz and low-pass filtered at 2 kHz prior to digitization. All experiments were performed at 24°C and the recording chamber was continually perfused with extracellular solution. To avoid receptor desensitization by repetitive agonist application, agonists were applied at intervals ≥3 min. An Octaflow II superfusion system (ALA Scientific Instruments) was used to apply the agonist for concentration-response studies. Applications were 500 ms at 6 psi. For the generation of concentration response curves, test pulses were applied to assess functional run-down (three pulses at 0.5 μM TC299423 or 1.0 μM TC299423 for α6-GFPβ2~DM~β3 and α4β2~DM~ nAChRs, respectively). Following the collection of the full concentration range an additional test pulse was repeated to assess accumulated desensitization.

### Data Analysis for Patch-Clamp Assays

Data were fit to a single Hill term using Origin 10 software. Data are expressed as mean ± SEM. The SEM values were calculated from the EC~50~ values obtained for each individual concentration-response obtained for α6-GFPβ2β3 or α4-GFPβ2 nAChRs (*n* =\> 5 and 4, respectively). For both α6-GFPβ2β3 and α4-GFPβ2 nAChRs we used peak current amplitude, normalized to the response of 1 μM TC299423.

Behavioral Assays
-----------------

For the mouse behavioral assays all drugs were dissolved in sterile 0.9% saline and were administered in an injection volume of 0.1 ml/g. Drug doses are expressed as free base.

Locomotor Assays
----------------

Mice were habituated to the experimental room for 2 h prior to the experiment. Horizontal locomotor activity was recorded using an infrared photobeam activity cage system (San Diego Instruments; San Diego, CA, United States). After habituating to the experimental room, mice were placed singly in a novel cage. Ambulations were recorded when two contiguous photobeams were broken in succession, preventing activity from being recorded by most sedentary animals. Ambulation events were measured for 45 min with four 15 s intervals per min. Mice were given a total of two intraperitoneal (*ip*) injections. First, mice were pre-injected with saline or 1 mg/kg mecamylamine before being placed in the activity cages. After 8 min in the cage they were removed, injected with the second drug (saline, nicotine, or TC299423), and returned again to the cage for the 45 min session.

### Conditioned Place Preference

Male, 3--6-month-old mice were used in our CPP assays. Various genotypes were used: WT, α6L9′S, α4L9′S (hypersensitive α4^∗^ and α6^∗^ nAChRs, respectively), α6KO, α4KO, and β2KO. All WT mice were C57BL/6J and all other genotypes have been backcrossed with C57BL/6J mice for ≥10 generations. The CPP apparatus (Med Associates, East Fairfield, VT, United States) was a rectangular cage with interior dimensions of 46.5 × 12.7 × 12.7(H) cm, divided into three sub-compartments: white and black (each 16.8 cm L) with steel mesh and rod floors, respectively, and a central gray compartment (7.2 cm L) with a solid plastic floor. Each compartment had a polycarbonate hinged lid for loading the animals. Drop-down doors separated the chambers.

Mice were housed singly and habituated to the experimental room for 3--7 days before initial testing and remained in the experimental room for the duration of the experiment. We chose a biased method for CPP. On day 1 (pre-training) mice were placed in the center chamber and allowed to explore the apparatus freely for 20 min. Time spent in each chamber was recorded, and drug pairing was determined by the least preferred chamber. Mice with a severe initial bias for one chamber (defined as ≥65% time spent in one conditioning chamber) were excluded. On days 2, 4, 6, and 8, mice were injected with the drug of interest, and were confined to the drug-paired chamber for 20 min. On days 3, 5, 7, and 9, mice were injected with saline and confined to the opposite chamber. On day 10 (post-training), mice were again given free access to the apparatus for 20 min, and the time spent in each chamber was recorded. CPP was determined by measuring the change in the difference between the time spent in the drug-paired chamber and the saline-paired chamber from pre- to post-training.

### Marble Burying Assay

Mice were habituated to the experimental room for ≥2 h prior to testing. Fifteen marbles were placed approximately 5 cm apart in a 5 × 3 marble grid in an activity cage, with 5 cm-deep bedding. Mice were given *ip* injections of saline, nicotine, varenicline, or TC299423 and placed in the cage with the marbles. After 10 min, the mice were returned to their home cages. Marbles were counted as buried if they were at least 75% covered with bedding. Each mouse was tested under each experimental condition using a Latin-square crossover design. A day without testing occurred between each test.

### Hot Plate Assay

Mice were again habituated to the experimental room for ≥2 h prior to testing. Mice were given *ip* injections of saline, nicotine, varenicline, or TC299423, 5 min before being placed on the hot plate apparatus (Harvard Apparatus, Holliston, MA, United States). This apparatus is a heated metal plate, maintained at 55°C, enclosed by a clear acrylic plastic cylinder (∼10 cm in diameter), within which the mouse is free to move. When a mouse exhibits evidence of discomfort (such as paw shaking, paw licking, jumping, or vocalization) or when a cut-off time of 60 s is reached, it is removed from the apparatus. If the mouse urinates during the assay, it is immediately removed from the hot plate. The time that the mouse remains on the hot plate prior to showing signs of discomfort is recorded. Doses were administered using a Latin-square crossover design. A day without testing occurred between each test.

### Rat Intravenous Self-Administration

Operant chambers (Med Associates, East Fairfield, VT, United States) were used for food delivery and the intravenous self-administration (IVSA) of nicotine. The chambers were equipped with two response levers (usually designated active and inactive) with a cue light located above each lever, a food pellet dispenser located between the levers, and a computer-controlled injection pump for the scheduled delivery of nicotine via an IV implanted catheter.

For IV catheter implantation, the rats were anesthetized using 1--3% isoflurane inhalation in oxygen and surgically prepared with catheters in the left jugular vein ([@B35]). The catheter was passed subcutaneously to a polyethylene assembly mounted on the animals' back. Prior to training, rats were food-restricted so that their body weight was approximately ∼85% that of free-feeding rats. They were then trained to press an active lever for 45 mg food pellets on a fixed ratio 5 time-out 20 s (FR5TO20) schedule of reinforcement. An inactive lever was also present in the operant box. Pressing this lever was recorded but was not associated with scheduled consequence. Rats were permitted to respond for food rewards until a reliable response was achieved, defined as \>90 pellets earned per 1 h session for three consecutive sessions. Rats were then permitted to respond for food (*n* = 8) or for nicotine infusions (*n* = 9) during 1 h daily sessions under the FR5TO20 schedule. Each food reward (45 mg pellet) or nicotine reward of 0.19 μmol/kg (0.03 mg/kg) per infusion over 1 s initiated a 20 s time-out period, signaled by a light cue located above the active lever, during which time pressing the active lever was without consequence.

Rats received *ip* injections of TC299423 (injection volume of 1 mL per 300 g weight). Twenty min after injection, rats were placed in the operant boxes and responding for food rewards or nicotine infusions was recorded. After each session, catheters were flushed with heparinized saline (30 U per mL) and checked for leaks or blockages. The effects of vehicle, or TC299423 doses of 0.01--0.08 mg/kg, on food or nicotine responding were assessed using a within-subjects Latin-square design. Each rat was permitted to respond for food or nicotine for at least two IVSA sessions between each TC299423 treatment to allow responding to return to baseline levels.

Off-Target Binding and Pharmacokinetic Data
-------------------------------------------

### Pharmacological Profiling

NovaScreen assays at PerkinElmer -- Caliper Life Sciences (Waltham, MA, United States) were used to evaluate the affinity of TC299423 on 70 diverse molecular targets *in vitro* using competition radioligand binding assays (see Supplementary Table [S3](#SM1){ref-type="supplementary-material"}).

### Pharmacokinetics

Pharmacokinetic experiments with TC299423 were performed by Absorption Systems LP (Exton, PA, United States). Eighteen male and female mice (20--40 g) were administered TC299423 at an *ip* dose of 0.3 mg/kg. Blood samples were taken and the brains were harvested 5 min, 15 min, 30 min, 1 h, 3 h, and 6 h after drug administration. Fifteen male and female mice (20--40 g) were administered TC299423 at a dose of 1 mg/kg orally. Blood and brain samples were obtained at the same time points as above. Untreated plasma and blood samples were collected from three mice in the same cohort as the study animals for pre-dose (time 0) samples. Blood samples were collected by cardiac puncture and stored in tubes containing sodium heparin before being processed. Plasma was prepared and frozen for analysis. Brains were harvested, rinsed, patted dry, weighed, and frozen.

The concentration of TC299423 in brain and plasma samples was measured using a generic LC-MS/MS method with a minimum 6-point calibration curve. Matched matrix was used for preparation of calibration standards. Dosing solutions were normalized in matched matrix and analyzed in triplicate in the same analytical batch as the incurred samples.

### Radioligand Displacement

Unbound TC299423 concentrations in the brain and blood of C57BL/6 mice were also measured using a radioligand displacement assay ([@B31]). Mice were administered 0.2 mg/kg (free base) TC299423 *ip*, and euthanized 5, 10, or 20 min after drug injection. Uninjected mice served as controls (*n* = 3 for each group). Trunk blood was collected into heparinized 1.5 mL polyethylene tubes. The tubes were centrifuged and the serum was collected. Some hemolysis occurred. The cerebral cortex was dissected, placed in 1 mL of cold water, homogenized, and diluted to 3 mL with cold water. Epibatidine saturation curves were constructed for the cortical samples using eight concentrations of \[^125^I\]epibatidine measured in triplicate (6, 12, 25, 50, 100, 200, 400, and 800 pM). The final assay volume was 500, and 50 μL of homogenate was added to each sample. Blanks included 100 μM nicotine. Samples were incubated at room temperature overnight. The samples were filtered, washed and counted. Inhibition of \[^125^I\]epibatidine (325 pM) binding was measured by adding 1, 2, 5, 10, or 20 μL of serum to samples. The washed, particulate fraction from C57BL/6 cortex was the source of the binding sites.

Results
=======

Identification of TC299423
--------------------------

In preparation for the present study, a small-molecule discovery program using a library of ∼7000 compounds of modest drugability was conducted at Targacept. Initial screenings of the library were conducted with few-concentration assays of Ca^2+^ flux and nAChR binding in transfected cell lines. Molecules with potential nanomolar to micromolar affinity for α6β2^∗^ nAChRs were sought. TC299423 (**Figure [1](#F1){ref-type="fig"}**), one of these compounds, was identified after our previous structure-activity relationship (SAR) studies on other nAChR subtypes ([@B7]; [@B88]; [@B77]) and on α6β2^∗^ nAChRs ([@B6]; [@B24]; [@B77]). TC299423 was also analyzed in computational studies on homology models of α6β2 binding sites analogous to those described previously ([@B77]). Assays that assessed metabolism were also conducted (discussed below, see Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). These initial experiments motivated the more detailed studies in the present paper, and in recently reported structure-function experiments ([@B64]; [@B63]).

![Relevant chemical structures. Structures for TC299423 (189 g/mol), (+)-PHT (molecular mass, 188 g/mol) which has also been tested as a potential α6^∗^ selective compound \[62\], nicotine (162 g/mol), 2-(pyridine-3-yl)quinuclidine (188 g/mol), a previous potential lead molecule from a series of metanicotine analogs ([@B6]; [@B24]), and metanicotine (162 g/mol).](fphar-08-00641-g001){#F1}

TC299423 can be considered an acrylic metanicotine analog (1 or 20a, **Figure [1](#F1){ref-type="fig"}**). In TC299423, the pyridine ring of nicotine was replaced by a pyrimidine ring, a substitution previously shown to increase α6^∗^ selectivity ([@B6]). We also incorporated the *N*-methyl moiety of the metanicotine into an additional, 8-membered ring (a 1,2,3,4,7,8-hexahydroazocine) in an effort to test a hypothesis that conformational constraints imposed by a cyclic structure would confer additional selectivity by reducing the conformational flexibility of the linear metanicotine structure.

Data obtained with an oocyte expression system showed that TC299423 exhibits a binding mode similar to that of nicotine at α6β2 nAChRs, forming a relatively weak cation-π interaction with a conserved tryptophan residue termed TrpB ([@B64]). At α4β2 nAChRs, this cation-π interaction also occurs. At α4β2 nAChRs, TC299423, like several other secondary ammonium agonists, makes an additional cation-π interaction with a conserved tyrosine termed TyrC2 ([@B63]).

Pharmacokinetics
----------------

The bioavailability of TC299423 was studied by measuring its plasma and brain concentration in mice after *ip* or oral administration (**Figure [2](#F2){ref-type="fig"}**). TC299423 reached a maximum plasma concentration of 49 ± 18 ng/ml (0.26 μM) 0.08 h after a 0.3 mg/kg *ip* injection and had a half-life of 0.17 h in the plasma (**Figure [2A](#F2){ref-type="fig"}**). It reached a maximum brain-tissue concentration of 22 ± 0.43 ng/g (0.12 μM) 0.5 h after *ip* injection (**Figure [2B](#F2){ref-type="fig"}**). Oral administration at 1 mg/kg resulted in a maximum plasma concentration of 38 ± 10 ng/ml (0.20 μM) after 0.25 h with a half-life of 1.12 h in the plasma (**Figure [2A](#F2){ref-type="fig"}**). A maximum brain-tissue concentration of 42 ± 17 ng/g (0.22 μM) was attained at 0.25 h (**Figure [2B](#F2){ref-type="fig"}**). Thus, TC299423 enters the plasma, and passes into the brain, before being completely metabolized. We used a previously described radioligand displacement assay ([@B31]) to obtain additional measurements of the TC299423 concentration in brain tissue *ex vivo* (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Similar to the previous pharmacokinetic assay, these data confirm the penetration of TC299423 into the brain and its availability to nAChRs, for ≥20 min.

![Pharmacokinetic measurements for TC299423. **(A)** Concentrations of TC299423 in plasma (ng/mL) following ip (0.3 mg/kg) and oral (1 mg/kg) administration. **(B)** Concentrations of TC299423 in the brain (ng/g) following ip (0.3 mg/kg) and oral (1 mg/kg) administration. All data are mean ± SEM. *n* = 3 mice. See text for conversion of ng/ml to μM.](fphar-08-00641-g002){#F2}

Some aspects of the microsomal metabolism of TC299423, in comparison to varenicline, were studied in preliminary experiments. In both human and rat microsomes, TC299423 exhibited a ∼7-fold longer half-life compared to varenicline (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). Using recombinantly expressed cytochrome P450 enzyme preparations, we also observed that TC299423 exhibits a more diverse degradation pathway than varenicline as it is metabolized by more isoforms of cytochrome P450 enzyme (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). These data suggest that several metabolic pathways contribute to TC299423 degradation. Thus, it is a candidate for more detailed human metabolism studies.

Potency and Efficacy of TC299423
--------------------------------

We used a variety of assays (whole-cell patch clamp, synaptosomal \[^3^H\]-dopamine release, synaptosomal \[^3^H\]-ACh release, \[^125^I\]-epibatidine binding, and ^86^Rb^+^ efflux) to measure TC299423 concentration-response relations for α4β2^∗^, α6β2^∗^, and α3β4^∗^ nAChRs. **Figure [3](#F3){ref-type="fig"}, Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}**, and Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}, summarize the data and show that TC299423 potently activates α6β2^∗^ nAChRs. The TC299423 concentration-response relations for α4β2 and α6β2β3 nAChRs were measured by transiently transfecting fluorescently tagged, mutant α4-GFPβ2~DM~ or α6-GFPβ2~DM~β3 nAChRs in neuro-2a cells, voltage clamping the cells (whole-cell mode), and applying TC299423 by rapid microperfusion (see Materials and Methods, **Figure [3A](#F3){ref-type="fig"}**). GFP-labeled nAChR subunits were used to facilitate the identification of neuro-2a cells expressing the transfected nAChRs and the DM mutation was used to increase the surface receptor density ([@B28]). EC~50~ values were determined by fitting the concentration-response data to the Hill equation. The EC~50~ of TC299423 on α4-GFPβ2~DM~ nAChRs was 0.1 ± 0.02 μM and on α6-GFPβ2~DM~β3 nAChRs was 0.04 ± 0.01 μM (**Figure [3A](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). The EC~50~ for the α6-GFPβ2~DM~β3 nAChRs was significantly less than that for α4-GFPβ2~DM~ nAChRs (*p* \< 0.05, two-tailed *t*-test). Thus TC299423 activated α6-GFPβ2~DM~β3 nAChRs significantly more potently than α4-GFPβ2~DM~ nAChRs.

![Concentration-response curves for functional responses of TC299423 on nAChRs. **(A)** Concentration-response relations of TC299423 on α4-GFPβ2~DM~ nAChRs (*n* = 5--13 cells) and α6-GFPβ2~DM~β3 nAChRs (*n* = 4 cells). **(B)** Measurement of α4β2^∗^-mediated α-CtxMII-resistant \[^3^H\]-dopamine release and α6β2^∗^-mediated (α-CtxMII-sensitive) \[^3^H\]-dopamine release from WT mouse striatal synaptosomes (see Materials and Methods). EC~50~ values for **(A,B)** are given in **Table [1](#T1){ref-type="table"}**. Data for \[^3^H\]-dopamine release were normalized to the maximum response calculated from the non-linear curve fits of the results to the Michaelis--Menten equation. Maximal response for the α-CtxMII-resistant release was calculated to be 6.06 ± 0.37 units and maximal response for the α-CtxMII-sensitive release was 0.93 ± 0.08 units. For comparison, 10 μM nicotine elicited 7.78 ± 0.83 units for α-CtxMII-resistant release and 3.63 ± 0.81 units for α-CtxMII-sensitive release. Data are mean ± SEM. SEM values for the normalized data were calculated using Taylor's expansion. Additional data are presented in the Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}. **(C,D)** Representative waveforms of voltage-clamp currents for TC299423 applications at given concentrations on α6-GFPβ2~DM~β3 and α4-GFPβ2~DM~ nAChRs. Waveforms are from a single cell for each nAChR subtype. Arrows indicate 500 ms applications and the dotted red line represents the baseline for measurements.](fphar-08-00641-g003){#F3}

###### 

EC~50~ values and Efficacy of TC299423 on nAChRs.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Assay                          Transfected nAChR Subunits in Neuro-2a Cells                                                                                   
  ------------------------------ ------------------------------------------------------- --------------------------------- -------------- --------------------- --------------------
  **Patch clamp** EC~50~ (μM)    0.04 ± 0.01                                             0.10 ± 0.02                                                            

                                                                                                                                                                

                                 **Probable nAChR subunit composition in mouse brain**                                                                          

  **Neurotransmitter release**   **α6β2^∗a^**                                            **α4β2^∗\ a^ Single component**   **α3β4^∗b^**   **α6β2^∗a^ (α5KO)**   **α4β2^a^ (α5KO)**

                                                                                                                                                                

  \% Efficacy\                   50 ± 20%\                                               76 ± 5%\                          100 ± 16%\     54 ± 14%\             112 ± 9%\
  EC~50~ (μM)                    0.03 ± 0.01                                             0.13 ± 0.03                       8.0 ± 0.4      0.05 ± 0.03           0.6 ± 0.1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Efficacy and Potency of TC299423 on stoichiometries of α4β2 nAChRs.

                                   α4β2^∗^ Two components   α4β2 (α5KO)   
  -------------------------------- ------------------------ ------------- -----------
  **^86^Rb^+^ efflux, Thalamus**                                          
  Efficacy                         139 ± 14%                32 ± 10%      166 ± 32%
  EC~50~ (μM)                      0.6 ± 0.1                10 ± 10       1.6 ± 0.5
  **^86^Rb^+^ efflux, Cortex**                                            
  Efficacy                         94 ± 7%                  39 ± 4%       169 ± 20%
  EC~50~ (μM)                      2 ± 2                    26 ± 21       2.4 ± 0.7

Efficacy values are given as a percent of the response to nicotine, 10 μM. EC

50

data are expressed as mean ± SEM. See Supplementary Figure

S1

for full concentration-response curves.

###### 

Binding *K*~i~ of TC299423 on nAChRs.

                                      α4β2^∗^ Single component   α6β2^∗^ (α4KO)   α3β4^∗^ (β2KO)
  ----------------------------------- -------------------------- ---------------- ----------------
  **\[^125^I\]epibatidine binding**                                               
  K~i~ (nM)                           0.24 ± 0.04                1.4 ± 0.6        18 ± 0.7

Data are expressed as mean ± SEM.

To compare the efficacy and potency of TC299423 for native α4β2^∗^ and α6β2^∗^ nAChRs, we measured TC299423-induced \[^3^H\]dopamine release from striatal synaptosomes (**Figure [3B](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Two classes of nAChR subtypes are responsible for nicotine-induced \[^3^H\]dopamine release from striatal synaptosomes: α-conotoxin MII (α-CtxMII)-sensitive and α-CtxMII-insensitive nAChRs. These classes are composed of α6β2^∗^ and α4(non-α6)β2^∗^ nAChRs, respectively. Accordingly, we measured concentration-response relations for the α-CtxMII-sensitive, and -insensitive, TC299423-induced \[^3^H\]dopamine release. As above, the EC~50~ values were obtained from fits to the Hill equation. The EC~50~ of TC299423 for α-CtxMII-insensitive \[^3^H\]dopamine release was 0.13 ± 0.03 μM and that for α-CtxMII-sensitive release was 0.03 ± 0.01 μM (**Figure [3B](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Thus, consistent with the patch-clamp data above, the TC299423--induced \[^3^H\]dopamine release assay also suggests that it activates α6β2^∗^ nAChRs more potently than α4β2^∗^ nAChRs. Both data sets suggest that TC299423 activates α6β2^∗^ nAChRs ∼3-fold more potently than α4β2^∗^ nAChRs. We also studied the effects of TC299423 on \[^3^H\]dopamine release using striatal synaptosomes from α5-KO mice. Genetic deletion of the α5 subunit did not significantly affect the potency of TC299423-induced α-CtxMII-sensitive, or -insensitive, \[^3^H\]dopamine release (**Table [1](#T1){ref-type="table"}**).

To study the potency of TC299423 for native α3β4^∗^ nAChRs, we prepared synaptosomes from the mouse interpeduncular nucleus, a region with dense α3β4 nAChR expression ([@B73]), and measured TC299423-induced \[^3^H\]ACh release. The EC~50~ for TC299423-induced \[^3^H\]ACh release was 8.0 ± 0.4 μM (**Table [1](#T1){ref-type="table"}**). Thus, TC299423 was much less potent at eliciting \[^3^H\]ACh release from interpeduncular nucleus synaptosomes than it was at eliciting \[^3^H\]dopamine release from striatal synaptosomes, suggesting that the drug activates α6β2^∗^ and α4β2^∗^ nAChRs more potently than α3β4^∗^ nAChRs.

The α4 and β2 nAChR subunits can form functional nAChRs with different subunit stoichiometries \[α4~(3)~β2~(2)~, α4~(2)~β2~(3)~\] and agonist sensitivities (low-, high-sensitivity, respectively). Receptors with the α4~(3)~β2~(2)~ stoichiometry are much less ACh-sensitive than those with the α4~(2)~β2~(3)~ stoichiometry ([@B54]; [@B37]). To compare the efficacy and potency of TC299423 for these two receptor stoichiometries, we measured TC299423-elicited ^86^Rb^+^ efflux from mouse thalamic and cortical synaptosomes (**Table [2](#T2){ref-type="table"}**). The α4(non-α6)β2^∗^ nAChRs mediate nicotinic agonist-induced ^86^Rb^+^ efflux from these synaptosomes ([@B45]). The nicotinic antagonist dihydro-β-erythroidine (DhβE) blocks high-sensitivity α4β2^∗^ nAChRs more potently than low-sensitivity α4β2^∗^ nAChRs ([@B46]) and can be used to distinguish between the two receptor stoichiometries. TC299423 had an EC~50~ of 0.6--2.0 μM for the DhβE-sensitive α4β2^∗^ nAChRs and ≥14 μM for the DhβE-insensitive α4β2^∗^ nAChRs (**Table [2](#T2){ref-type="table"}**). Thus, TC299423 more potently activates high-sensitivity α4~(2)~β2~(3)~, than low-sensitivity α4~(3)~β2~(2)~, nAChRs.

Regarding efficacy, previous data with an oocyte expression system showed that TC299423 is a partial agonist at α6β2 nAChRs, with an efficacy 59% that of ACh itself ([@B64]). In the present experiments on neurotransmitter release, we found additional evidence that TC299423 is a partial agonist at α6β2^∗^ receptors: the maximal release by TC299423 was 50--54% that of nicotine (**Table [1](#T1){ref-type="table"}**).

We find that TC299423 is roughly as efficacious as nicotine for high-sensitivity α4β2^∗^ nAChRs, but a partial agonist on low-sensitivity α4β2^∗^ nAChRs (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). Interestingly, it also appears to be at least as efficacious as nicotine for α4β2^∗^ nAChRs lacking the α5 nAChR subunit (**Figure [1](#F1){ref-type="fig"}, Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**, and Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). We also find that TC299423 is roughly as efficacious as nicotine for α3β4^∗^ nAChRs.

Binding Affinity of TC299423
----------------------------

To determine whether TC299423 displays a higher affinity for β2^∗^, than β4^∗^, nAChRs, we measured its ability to displace \[^125^I\]epibatidine binding to membranes from three brain regions (see Materials and Methods). \[^125^I\]Epibatidine binds predominantly to the α4β2^∗^ subtype in cortical membranes, α3β4^∗^ in IPN membranes from β2KO mice, and α6β2^∗^ in striatal membranes from α4KO mice ([@B24]). Thus, the set of *K*~i~ values for TC299423 to displace \[^125^I\]epibatidine binding in these three regions provides a way to measure the apparent affinity of these three subtypes. Based on these measurements, the *K*~i~ values for the α4β2^∗^, α6β2^∗^, and α3β4^∗^ subtypes were 0.24 ± 0.04, 1.4 ± 0.6, and 18.0 ± 0.7 nM, respectively (**Table [3](#T3){ref-type="table"}**). Thus, TC299423 binds with higher affinity to α4β2^∗^ and α6β2^∗^, than α3β4^∗^ nAChRs. *K*~i~ values primarily reflect agonist binding to the high-affinity, desensitized state, whereas EC~50~ values for functional assays reflect agonist binding to the free-receptor state. The relationship between the *K*~i~ for \[^125^I\]epibatidine displacement (**Table [3](#T3){ref-type="table"}**) and the EC~50~ for \[^3^H\]dopamine release (**Table [1](#T1){ref-type="table"}**) for the α4β2^∗^ and α6β2^∗^ nAChRs is consistent with previous results showing that α6^∗^ nAChRs display a ∼10-fold lower *K*~i~ than EC~50~, whereas α4^∗^ nAChRs display a ∼100-fold difference. Here, we observed a ∼20-fold difference for α6β2^∗^ nAChRs and a ∼500-fold difference for α4β2 nAChRs. This comparison suggests that agonist-induced, steady-state desensitization is less pronounced for α6β2^∗^, than α4β2^∗^, nAChRs ([@B26]).

TC299423 Activity on Non-nAChR Targets
--------------------------------------

TC299423 was assessed for binding to 70 different receptors and other targets at a concentration of 1 μM (Supplementary Table [S3](#SM1){ref-type="supplementary-material"}). Assays included the nicotinic drug \[^3^H\]epibatidine binding to α-bungarotoxin-insensitive nAChRs, the 5-HT3 inhibitor \[*N*-*methyl*-^3^H\]GR65630 to mouse receptors in N1E-115 cells, and human receptors expressed in a clonal cell line. Other assays included monoamine oxidase A, monoamine oxidase B, 5-HT transporter, norepinephrine transporter, and dopamine transporter, as well as other. G-protein-coupled receptors, ion channels, enzymes, and transporters. The results showed that, consistent with the results reported here, TC299423 bound to neuronal nAChRs (measured by \[^3^H\]epibatidine displacement). It also bound to ATP-sensitive potassium channels, but with a much lower affinity than to nAChRs. Only these two sites showed significant binding. Thus, off-target effects are unlikely to confound our experimental data at TC299423 concentrations ≤1 μM.

TC299423 and Reward-Related Behavior
------------------------------------

Previous data show that mutant mice expressing hypersensitive α6L9′S^∗^ nAChRs are more sensitive to nicotine-induced CPP than WT mice, suggesting that α6^∗^ nAChR activation on its own can induce CPP ([@B17]). Our functional data show that TC299423 exhibits a modest preference for activating α6^∗^ nAChRs. Thus, CPP was used to test whether the activation of α6^∗^ nAChRs by TC299423 is rewarding in mice (**Figure [4](#F4){ref-type="fig"}**). We tested the ability of TC299423 to establish CPP in both WT, and mutant α6L9′S, mice. Mice were injected with zero (saline-injected), 1, 4, 12, or 25 μg/kg TC299423 during CPP training (see Materials and Methods). TC299423 had a highly significant overall effect on the CPP difference score in the mutant α6L9′S mice \[One-way ANOVA, *F*~(4,45)~ = 6.706, *p* = 0.0003\], but not in WT mice \[One-way ANOVA, *F*~(4,60)~ = 1.442, *p* = 0.2312\] (**Figures [4A,B](#F4){ref-type="fig"}**). *Post hoc* comparisons (Tukey HSD) showed that the scores of α6L9′S mutant mice injected with 1 and 25 μg/kg TC299423 were significantly greater than the saline-injected controls (*p* \< 0.05, **Figure [4B](#F4){ref-type="fig"}**). The ability of low doses of TC299423 to elicit CPP in the α6L9′S mice suggests that it is rewarding for these mice. Interestingly, the CPP difference scores for the saline-injected WT and mutant controls also suggest that WT mice habituate to the stress of repeated confinement in the least preferred chamber (i.e., their CPP difference scores are positive), while α6L9′S mutant mice become sensitized to it (i.e., their CPP difference scores are negative). For the WT mice, the CPP dose-response data were fitted to the Michaelis--Menten equation (see Materials and Methods) with an ED~50~ value of 4 ± 3 ng/kg, whereas the lowest dose tested for the α6L9′S mice elicited a near maximal response, consistent with an ED~50~ value \< 1 ng/kg (**Figures [4A,B](#F4){ref-type="fig"}**). This confirms that mice with hypersensitive α6L9′S^∗^ nAChRs were more sensitive to TC299423-induced CPP than WT mice. Thus, low doses of TC299423 are more rewarding for the hypersensitive α6L9'S mutant mice than the WT.

![Conditioned place preference (CPP) by genotype and dose. **(A)** WT mice were trained with TC299423 using a range of doses (0, 1, 4, 12, and 25 μg/kg) in a CPP assay (*n* = 8--23). A Michaelis--Menten curve was fitted to the data. The ED~50~ was 4 ± 3 μg/kg. **(B)** α6L9′S mice were trained in a CPP assay using the same doses as in **(A)** (*n* = 8--10). A Michaelis--Menten curve is drawn on the data with an ED~50~ of 0.3 ng/kg to guide the eye; but the data would be equally well described by any ED~50~ \< 1 ng/kg. **(C)** Mice of various genotypes were trained with TC299423 (12 μg/kg) in a CPP assay (*n* = 9--23 mice). For all panels, data shown are mean ± SEM: ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 (one-way ANOVA with *post hoc* Tukey).](fphar-08-00641-g004){#F4}

Even though TC299423 had no significant overall effect on CPP in the WT mice (one-way ANOVA, Tukey HSD, *p* = 0.23), a *t*-test revealed a marginally significant increase in CPP difference score for the 0.012 mg/kg TC299423-injected group, compared to the saline-injected control (*p* = 0.047) (**Figure [4A](#F4){ref-type="fig"}**). Using this dose, we examined the importance of individual nAChR subunits on TC299423 reward-related behavior. We compared WT mice to α6KO, α4KO, and β2KO mice, all injected with 0.012 mg/kg TC299423. Here, we observed a significant overall different response to TC299423 among the genotypes \[one-way ANOVA, *F*~(3,47)~ = 4.825, *p* = 0.005\] (**Figure [4C](#F4){ref-type="fig"}**). Genetic deletion of the α6 and β2 subunits dramatically reduced the CPP difference scores (*p* \< 0.05), whereas deletion of the α4 subunit had no effect on the difference scores (**Figure [4C](#F4){ref-type="fig"}**). These data suggest that (1) a low dose of TC299423 (0.012 mg/kg) is weakly rewarding for WT mice, and (2) this rewarding effect is mediated by the activation of α6(non-α4)β2^∗^ nAChRs.

Food Rewards or Nicotine IVSA
-----------------------------

The CPP data above suggest that low doses of TC299423 are weakly rewarding for WT mice but do not provide any information about the potential effects of TC299423 on the motivational properties of other substances, such as food and nicotine. Previous results show that nAChR partial agonists such as varenicline and (+)-PHT (**Figure [1](#F1){ref-type="fig"}**) block nicotine-induced IVSA and CPP ([@B67]; [@B10]). Thus, we tested the effects of TC299423 on male Wistar rats trained to press a lever for food pellets or intravenous nicotine infusions (**Figure [5](#F5){ref-type="fig"}**).

![TC299423 does not alter nicotine IVSA. Pre-injection of TC299423 in rats at doses of 0.01, 0.025, 0.05, or 0.08 mg/kg did not affect food intake **(A)** or nicotine IVSA **(B)** compared to vehicle control (saline). (A1) Dose-response relation for earned food rewards (*n* = 8) (ns, *p* = 0.9967). (A2) Dose-response relation for active lever presses during food responding (ns, *p* = 0.7861). (B1) Dose-response relation for earned nicotine infusions (0.03 mg/kg) (*n* = 9) (ns, *p* = 0.6331). (B2) Dose-response relation for active lever presses during nicotine self-administration (ns, *p* = 0.5798). Data presented are mean ± SEM and analyzed using one-way repeated measures ANOVA.](fphar-08-00641-g005){#F5}

Rats were trained using 45 mg food pellets on a FR5TO20 schedule. Rats were then permitted to respond for food (*n* = 8) or nicotine infusions (0.03 mg/kg/inf) (*n* = 9) during 1 h daily sessions under the FR5TO20 schedule. TC299423 or vehicle was administered (*ip*, 1 mL/300 g weight, doses indicated in **Figure [5](#F5){ref-type="fig"}**) 20 min before placement in operant boxes. Compared to vehicle, rats pre-injected with doses of 0.01, 0.025, 0.05, or 0.08 mg/kg TC299423 showed no statistically significant changes in responding for food pellets or nicotine infusions \[one-way ANOVA: Nicotine (*p* = 0.6331), Food (*p* = 0.9967)\]. In neither case did TC299423 change the number of active lever presses. Thus, low-dose TC299423 did not inhibit the rewarding effects of food or nicotine.

TC299423 Effect on Locomotion
-----------------------------

Locomotor responses to novel stimuli are an index of animal exploration and anxiety that can also provide a predictive factor for responses to rewarding drugs ([@B2]). Mice that exhibit greater motor activity (high responders) in a novel environment are more likely to be susceptible to rewarding properties of drugs, compared to mice that exhibit low activity (low responders). Thus, we used a locomotor assay to compare the *in vivo* effects of low doses of TC299423 and nicotine on WT and α6L9′S mice (see Materials and Methods, **Figure [6A](#F6){ref-type="fig"}**). Mice were injected *ip* with saline, nicotine (0.08 mg/kg), or TC299423 (0.09 mg/kg) and their ambulatory activity in a novel environment was recorded (**Figure [6A](#F6){ref-type="fig"}**). (Doses of 0.08 mg/kg nicotine and 0.09 mg/kg TC299423 are equimolar, 0.5 μmol/kg). To determine whether the effects of nicotine and TC299423 on ambulation were driven by nAChR activation, the mice were also pre-injected with either saline or mecamylamine (1 mg/kg) (**Figure [6A](#F6){ref-type="fig"}**). Both genotype and drug treatment significantly affected ambulation \[two-way ANOVA: genotype, *F*~(1,72)~ = 15.98, *p \<* 0.005; drug effect, *F*~(5,72)~ = 7.70, *p* \< 0.005\]. Nicotine and TC299423 at these doses dramatically increased the ambulatory activity of the mutant α6L9′S, but not WT, mice (**Figure [6A](#F6){ref-type="fig"}**). The increases were blocked by mecamylamine pre-injections. Neither TC299423 nor nicotine affected WT ambulation, and there were no significant differences between the ambulatory activity of WT and α6L9′S mice pre-injected mecamylamine. Interestingly, even the saline-injected α6L9′S mice showed significantly more ambulation than the WT (*p* \< 0.01). This difference was also blocked by mecamylamine pre-injection (**Figure [6A](#F6){ref-type="fig"}**), suggesting that it is mediated by the endogenous activation of α6L9′S^∗^ nAChRs. Thus, consistent with the CPP results above and previous data ([@B18]), the locomotor response of the mutant α6L9′S mice was more sensitive to nicotine and TC299423 than that of the WT mice. The locomotor data also confirm the activation of α6L9′S^∗^ nAChRs by a low dose of TC299423 (0.09 mg/kg in this case).

![Locomotor, anxiolytic and analgesic effects of TC299423. **(A)** Locomotor activity of WT and α6L9′S mice in a novel environment. Mice were injected ip with saline, 0.08 mg/kg nicotine, or 0.09 mg/kg TC299423, and their locomotor activity was measured. Mice were also pre-injected with saline or 1 mg/kg mecamylamine prior to testing (*n* = 8--32). Pre-injection with mecamylamine blocked nicotine- and TC29942-mediated increase in locomotor activity in the α6L9'S mice. **(B)** The effects of nicotine, varenicline, and TC299423 (0.3 mg/kg for each) on antinociception were measured using the hot-plate test (*n* = 7--8 mice). **(C)** The effects of nicotine, varenicline, and TC299423 (0.3 mg/kg for each) on marble burying were measured (*n* = 8--11 mice). In all panels, data presented are mean ± SEM: ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 \[Two-way ANOVA with *post hoc* Tukey **(A)** or One-way ANOVA with *post hoc* Tukey **(B,C)**\].](fphar-08-00641-g006){#F6}

TC299423 Effect on Antinociception
----------------------------------

Previous data show that nicotine is antinociceptive and this effect is mediated by α4β2^∗^ ([@B13]) and α6^∗^ nAChRs ([@B84]). Because TC299423 is an agonist for α4β2^∗^ nAChRs at higher doses, we tested its antinociceptive properties at a dose of 0.3 mg/kg in WT mice using a hot plate assay, and compared its antinociceptive properties to those of 0.3 mg/kg nicotine and 0.3 mg/kg varenicline (**Figure [6B](#F6){ref-type="fig"}**). The drug treatments significantly affected responses of WT mice measured with the hot plate test \[One-way ANOVA, *F*~(3,27)~ = 6.826, *p* = 0.0014\]. The antinociception elicited by TC299423 was similar to that elicited by 0.3 mg/kg nicotine. The antinociceptive effects of both nicotine and TC299423 were significantly greater than that of varenicline (**Figure [6B](#F6){ref-type="fig"}**, *p* \< 0.05).

TC299423 Effect on Anxiety-Related Behavior
-------------------------------------------

The anxiolytic effects of nicotine may contribute to its rewarding effects, and appear to be mediated by α4β2^∗^ nAChRs ([@B80]; [@B1]). Marble burying behavior is a widely used ([@B15]; [@B87]) measure of anxiety-related and compulsive behavior in mice, though interpretation may be complex ([@B79]; [@B85]). To compare the anxiolytic properties of TC299423, varenicline, and nicotine, WT mice were administered saline, nicotine (0.3 mg/kg), varenicline (0.3 mg/kg), or TC299423 (0.3 mg/kg) and evaluated with the marble burying test (**Figure [6C](#F6){ref-type="fig"}**). Overall, the drugs significantly affected the number of marbles buried \[One-way ANOVA, *F*~(3,33)~ = 45.65, *p* \< 0.001\]. Mice buried significantly fewer marbles following nicotine, TC299423, or varenicline administration than following saline administration. Further, mice buried fewer marbles after nicotine or TC299423 injections than varenicline injections (*p* \< 0.001, **Figure [6C](#F6){ref-type="fig"}**). Note that neither nicotine, nor TC299423, significantly reduced locomotion in WT mice (**Figure [6A](#F6){ref-type="fig"}**), rendering it unlikely that the decrease in marble burying is caused by physical sedation.

Discussion
==========

Our results show that TC299423 is a potent and selective agonist for α6β2^∗^ and α4β2^∗^ nAChRs, compared to α3β4^∗^ nAChRs (**Figure [3](#F3){ref-type="fig"}** and **Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). In addition, radioligand displacement assays indicate that TC299423 exhibits virtually no off target interactions (see Supplementary Table [S3](#SM1){ref-type="supplementary-material"}). TC299423 is orally available and crosses the blood-brain barrier (**Figure [2](#F2){ref-type="fig"}** and Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). TC299423 has a longer half-life than nicotine ([@B59]) and remains in the brain for at least 60 min following *ip* injection or oral administration. Experiments with synaptosomes show that TC299423 elicits α6^∗^ nAChR-mediated, striatal \[^3^H\]dopamine release. Consistent with these data, behavioral assays such as CPP (**Figure [4](#F4){ref-type="fig"}**) and locomotion in a novel environment (**Figure [6A](#F6){ref-type="fig"}**), which depend on dopamine release, suggest that TC299423 can elicit dopamine release *in vivo*. TC299423 is roughly as effective as nicotine in eliciting locomotor responses in α6L9′S mice (**Figure [6A](#F6){ref-type="fig"}**). Thus, TC299423 is a novel nAChR agonist that may be useful in studying of nAChR function and physiology in both *in vitro* and *in vivo* systems.

Our *in vitro* and *in vivo* data characterizing the properties of TC299423, along with those reported on the tropane compound, (+)-pyrido\[3,4\]homotropane \[(+)-PHT\] ([@B10]) (see **Figure [1](#F1){ref-type="fig"}** for structure), are promising indications that selective α6β2^∗^ nAChR agonists can be identified. Given the pharmacological similarities between α6^∗^ and α4^∗^ nAChRs ([@B6]), it has been challenging to identify agonists that show even modest selectivity. Previous studies indicate that nicotine is more potent on α4(non-α6)β2^∗^-nAChRs than it is on α6(non-α4)β2^∗^ nAChRs, though it is even more potent on α4α6β2^∗^ nAChRs ([@B70]; [@B82]; [@B24]). TC299423, in contrast, appears to be more potent at α6(non-α4)β2^∗^ than at α4(non-α6)β2^∗^-nAChRs (see **Table [1](#T1){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). Also, it is encouraging that the fold difference between the EC~50~ values for α6β2^∗^ vs. α4β2^∗^ nAChRs is consistent using two distinct assays for receptor function: patch-clamp assays on identified subtypes expressed in cultured cells and \[^3^H\]dopamine release assays using mouse synaptosomes (see **Table [1](#T1){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). A similar pattern was observed for (+)-PHT ([@B10]), but TC299423 is considerably more potent than (+)-PHT. An analog of TC299423, 2-(pyridine-3-yl)quinuclidine \[see **Figure [1](#F1){ref-type="fig"}** and ([@B24])\], also exhibited a similar pattern in potency among α6β2^∗^ and α4β2^∗^ nAChRs. However, PHT was also relatively potent on α3β4 and α7 nAChRs (EC~50~ values of 0.43 and 0.66 μM, respectively). Thus, TC299423 is a notable advance compared to our previous series of small molecules ([@B6]; [@B24]). Although TC299423 shows a preference for α6^∗^ nAChRs, the difference in potency between α6^∗^ and α4^∗^ nAChRs is not sufficient to label it as an α6^∗^ selective drug. Thus, the identification of a truly selective small molecule for α6^∗^ nAChRs is still to come.

Our pharmacokinetic assays confirm that oral and *ip* administrations of TC299423 achieve brain concentrations that are sufficient for activating nAChRs. Hence, we investigated the rewarding properties of TC299423 using CPP and nicotine IVSA assays. Pharmacological and gene deletion studies show that the β2, α4, and α6 nAChR subunits are critical for nicotine-induced CPP ([@B83]; [@B72]). Transgenic mice expressing hypersensitive α6^∗^ nAChRs exhibit significant CPP in response to a range of TC299423 doses (see **Figure [4](#F4){ref-type="fig"}**). TC299423 doses in this range do not have a significant overall effect on CPP in WT mice. However, significant differences between the CPP of WT and nAChR KO mice (α6KO and β2KO) in response to a single TC299423 dose (0.012 μg/kg) suggest that: (1) it has a weakly rewarding effect at this dose in WT mice, and (2) α6 and β2 nAChR subunits (but not α4) mediate this effect (see **Figure [4A](#F4){ref-type="fig"}**). We did not observe any difference between TC299423-induced CPP in the WT and α4KO mice. Thus, the rewarding effects of TC299423 at this dose are likely to be mediated by α6(non-α4)β2^∗^ nAChRs, rather than α4α6β2^∗^ or α4β2 nAChRs. Our KO data also suggest that TC299423 reward-related behavior in WT and α6L9′S mice is mediated via nAChRs, rather than via off-target responses. The contribution of the α6^∗^ nAChRs to TC299423-induced CPP is reinforced by its potency in establishing CPP in the α6L9′S mice (see **Figure [4C](#F4){ref-type="fig"}**). The enhanced sensitivity of α6L9′S mice to TC299423-induced CPP is consistent with previous cellular and behavioral data showing an enhanced sensitivity to nicotine as well ([@B18]; [@B19]). Interestingly, the effects of TC299423 on CPP in α6KO and α4KO differ from that of nicotine ([@B72]). (+)-PHT also elicits CPP in mice, but at higher doses than TC299423 ([@B10]).

We did not find any effects of low-dose TC299423 on nicotine IVSA or food reward in rats. Nicotine has reinforcing behavioral effects through activation and desensitization of nAChRs in the central nervous system. β2^∗^ nAChRs, which often contain α4 and/or α6 subunits, are necessary for nicotine IVSA and CPP ([@B61]; [@B49]; [@B83]). α4^∗^ nAChRs are sufficient for establishing nicotine CPP ([@B78]; [@B52]), but apparently not necessary ([@B9]). They are also important, if not necessary, for nicotine IVSA ([@B9]). Similarly, α6^∗^ nAChRs are sufficient for nicotine CPP ([@B17]), but not necessary ([@B72]), and appear to be necessary for nicotine IVSA ([@B62]). Recent investigations using smoking-relevant concentrations of nicotine highlight the importance of activating VTA nAChRs that contain both the α4 and α6 nAChR subunits ([@B39]; [@B20]) and suggest that α4α6β2^∗^ nAChRs are a primary target for nicotine. In the context of nicotine IVSA, α4^∗^, α6^∗^, and β2^∗^ nAChRs are certainly involved, but one must also consider the involvement of α4α6β2^∗^ nAChRs.

While TC299423 had no effect on nicotine IVSA, several nAChR ligands have been shown to reduce nicotine IVSA: varenicline ([@B67]), sazetidine-A ([@B56]), mecamylamine ([@B16]; [@B21]), bupropion ([@B8]), and cytisine ([@B66]). Multiple mechanisms can account for the failure of a low-dose of TC299423 to suppress nicotine IVSA. First, the suppressive effects of nicotine, varenicline, and sazetidine-A may arise from their effects on α4β2^∗^, rather than α6β2, nAChRs. Second, the rewarding effects of TC299423 at the dosages used may be insufficient to substitute for those of nicotine. Third, we note a key difference between TC299423 and drugs that have been shown to alter nicotine reinforcement: varenicline, cytisine, and bupropion are all partial agonists shown to decrease nicotine IVSA or nicotine CPP ([@B8]; [@B68]) but they also act as nAChR antagonists ([@B74]; [@B53]; [@B57]). Additionally, previous studies show that potent nAChR antagonists decrease nicotine CPP and nicotine IVSA ([@B16]; [@B72]). We did not observe that TC299423 acts as an antagonist on nAChRs and this could be a key mechanistic reason why it does not alter nicotine reinforcement. Finally, TC299423 may enhance both the reinforcing and aversive properties of nicotine, effectively neutralizing the effects on nicotine IVSA. There is a dense population of α6^∗^ nAChRs in the medial habenula ([@B28]; [@B73]) and this region regulates nicotine aversion ([@B22]). However, all reports of this phenomena point to α2^∗^, α5^∗^, and β4^∗^ nAChRs mediating aversion to nicotine ([@B69]; [@B22]); and direct involvement of α6 nAChR subunits has yet to be examined. If α6^∗^ nAChRs also mediate aversive responses in the medial habenula, TC299423 stimulation of α6^∗^ nAChRs may produce a simultaneous enhancement of rewarding and aversive stimuli. While it is currently unknown whether α6^∗^ nAChRs play a role in nicotine aversion, we note that α6^∗^ nAChRs play a critical role in affective nicotine withdrawal behavior ([@B32]).

Nicotine's anxiolytic and analgesic properties are also considered contributing factors to nicotine addiction. We measured anxiety-related behavior and nociception in mice using the marble burying and hot-plate assays, respectively. Nicotine's anxiolytic and nociceptive properties are believed to be primarily mediated by α4β2^∗^ nAChRs ([@B5]; [@B81]; [@B80]; [@B88]; [@B29]). Thus, we used a higher dose of TC299423 for these assays (0.3 mg/kg) than in the CPP assays, to ensure activation of α4β2^∗^ receptors. We found that TC299423 resembles nicotine in both its anxiolytic and antinociceptive properties, and is more potent and/or efficacious in each than varenicline (see **Figure [6](#F6){ref-type="fig"}**).

Overall, our results represent a thorough pharmacological investigation (*in vivo* and *in vitro*) of the novel nAChR agonist, TC299423. Our data suggest that TC299423 is a full agonist at α4β2^∗^ nAChRs and support a previous conclusion that TC299423 is a partial agonist at α6β2^∗^ nAChRs ([@B64]). Similar to CNS penetrant nAChR partial agonists (e.g., varenicline), TC299423 potently activates β2^∗^ nAChRs and exhibits suitable pharmacokinetic characteristics for use *in vivo.* TC299423 potently elicits reward-related behavior in hypersensitive α6L9′S mice and perhaps WT mice. At low doses, TC299423-initiated reward is primarily mediated through α6^∗^ nAChRs, not α4^∗^ nAChRs. Our studies of TC299423 and nicotine IVSA show that TC299423 at the low doses we tested is not efficacious in altering nicotine reinforcement. Nevertheless, TC299423 is a potent and novel nAChR agonist that could be useful for the future study of nAChR-related function and physiology.
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